short chain dehydrogenase/reductase family 39U member 1Genealiases: C14orf124 · HCDI
Q-omics provides the consensus-scored SDR39U1 profile across patient tissues and cancer cell-line models. SDR39U1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SDR39U1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SDR39U1 protein abundance shows 23,242 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight PAAD, KIRC, and PDAC as cancer lineages where SDR39U1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDR39U1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDR39U1 survival associations across molecular data types. SDR39U1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDR39U1 RNA expression–survival associations across cancer types. High SDR39U1 expression shows unfavorable associations in UVM and COAD, but favorable associations in PAAD, UCS, BRCA and KIRP. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for SDR39U1 RNA expression.
This table summarizes SDR39U1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SDR39U1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDR39U1 shows lower tumor expression in KIRC, THCA, KIRP and BRCA and higher tumor expression in LIHC and COAD. The KIRC box plot shows higher SDR39U1 RNA expression in normal versus tumor tissue (log2 FC = −0.695, t-test p < 0.001).
This table shows molecular features associated with SDR39U1 in patient tissues and cancer cell lines. In patient samples, SDR39U1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SDR39U1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
